

Title Page

Title: Incidence of primary open angle glaucoma in the Andhra Pradesh Eye Disease Study (APEDS)

Running Head: 15-year incident POAG in APEDS

Authors:

Nikhil S. Choudhari, DNB,^{1,2}

Rohit C Khanna MD,²⁻⁵

Srinivas Marmamula Ph.D.,^{2,3,6}

Asha Latha Mettla MSc,^{2,3}

Pyda Giridhar Ph.D.,^{2,3}

Seema Banerjee B.Opt,^{2,3}

Konegari Shekhar DOA,^{2,3}

Subhabrata Chakrabarti Ph.D.,³

Gudlavalleti VS Murthy MD,^{7,8}

Clare Gilbert FRCOphth,⁸

Gullapalli N Rao MD^{2,3} and

Andhra Pradesh Eye Disease Study Group*

Institute Affiliation:

1. VST Glaucoma Centre, Dr. Kallam Anji Reddy Campus, L V Prasad Eye Institute, Banjara Hills, Hyderabad, India.
2. Allen Foster Community Eye Health Research Centre, Gullapalli Pratibha Rao International Centre for Advancement of Rural Eye care, L V Prasad Eye Institute, Kismatpur Road, Himayathsagar, Telangana State, India
3. Brien Holden Eye Research Centre, L V Prasad Eye Institute, Banjara Hills
4. School of Optometry and Vision Science, University of New South Wales, Sydney, Australia
5. University of Rochester, School of Medicine and Dentistry, Rochester, NY, USA
6. Wellcome Trust / Department of Biotechnology India Alliance, L V Prasad Eye Institute, Hyderabad, India
7. Indian Institute of Public Health, Madhapur, Hyderabad, India,

31 8. International Centre for Eye Health, Department of Clinical Research, London School
32 of Hygiene & Tropical Medicine, London, United Kingdom

33 *Andhra Pradesh Eye Disease Study Group: Maneck Nicholson MD,² Raghava JV MD,²
34 Sahitya T MD,² Lavanya EY MD,² Hira B Pant PGDBDM,⁴ Ritu Dixit, MS,³ Goutham
35 Pyatla,³ Alice Arati Anthony³, Syed Hameed³, Samir Bera³, Sneha Kumari³ and Inderjeet
36 Kaur PhD³

37 **Corresponding Author:**

38 Rohit C Khanna,

39 Full Postal Address: L V Prasad Eye Institute, Dr. Kallam Anji Reddy Campus, L V Prasad
40 Marg, Banjara Hills, Hyderabad 500 034 Andhra Pradesh, India

41 Phone: 91-40-3061 2646 (Office), Fax: 91-40-2354 8271

42 E-Mail: rohit@lvpei.org

43 **Funding support:** Hyderabad Eye Research Foundation, India, Lions Clubs International
44 Foundation, SightFirst Research grant, USA, and Department of Biotechnology, Centre of
45 Excellence (CoE) grant, India.

46 **Conflicts of interest:** None of the authors

47 This submission has not been published anywhere previously and it is not simultaneously
48 being considered for any other publication.

49

50 **ABSTRACT**

51 **Background:** To report 15-year incidence rate of primary open angle glaucoma (POAG) in
52 the Andhra Pradesh Eye Disease Study (APEDS)

53 **Methods:** A population-based longitudinal study was carried out at three rural study sites.
54 Phakic participants aged ≥ 40 years who participated at baseline (APEDS I) and the mean 15-
55 year follow-up visit (APEDS III) were included. A comprehensive ophthalmic examination
56 was performed on all participants. Mean intraocular pressure (IOP) was average of IOPs of
57 right and left eyes. The definition of glaucoma was based on the International Society of
58 Geographical and Epidemiological Ophthalmology (ISGEO) classification. The main outcome
59 measure was incidence of POAG during the follow-up period in participants without glaucoma
60 or suspicion of glaucoma at baseline.

61 **Results:** Data from the available and eligible participants from the original cohort (1241/2790;
62 44.4%) were analyzed. The mean age (standard deviation) of participants at baseline was 50.2
63 (8.1) years; 580 (46.7%) were men. Thirty-six participants developed POAG [bilateral in 17
64 (47.2%)] over 15 years. The incidence rate of POAG per 100-person years (95% confidence
65 interval) was 2.83 (2.6, 3.08). Compared to baseline, the reduction in mean IOP [median
66 (range) mm Hg] was -0.75 (-7.5, 9) in participants with incident POAG and -2.5 (-14.5, 14.5) in
67 those without. The inter-visit difference in mean IOP was a significant risk factor on logistic
68 regression analysis.

69 **Conclusion:** We report the long-term incidence of POAG in rural India. A longitudinal change
70 in IOP, specifically a less pronounced reduction in IOP with increasing age, was a novel risk
71 factor.

72

73 **INTRODUCTION**

74 Glaucoma may be defined as an intraocular pressure-dependent optic neuropathy with
75 progressive loss of neural tissue and consequent visual field defects. It is one of the leading
76 causes of blindness. The global, age-standardized prevalence of glaucoma in populations aged
77 ≥ 40 years was estimated to be 3.5% in 2013,¹ affecting 64 million people aged 40-80 years.
78 Nearly 70% of those affected have primary open angle glaucoma (POAG). With increasing
79 longevity, the number with glaucoma is projected to increase to over 110 million by 2040.²
80 The prevalence of POAG is highest in Africa and lowest in Asia.² The pathogenesis of POAG
81 is not fully elucidated and is likely to entail genetic factors, and mitochondrial dysfunction is
82 also being explored as a pathogenic mechanism.¹ Currently the only modifiable risk factor for
83 POAG is intraocular pressure (IOP). Other risk factors include ethnic group, a positive family
84 history of glaucoma, older age and high myopia.¹ In addition, some non-communicable
85 diseases are associated with POAG.³

86 Prevalence and incidence studies provide complementary information about the
87 epidemiology of a disease. While the former estimates the burden of a disease, the latter can
88 provide information about the etiology of a disease and its outcome. However, there are only a
89 few population-based studies on the incidence of POAG,⁴⁻¹² including studies in India⁴ or of
90 populations of Indian origin.⁵

91 The Andhra Pradesh Eye Disease Study (APEDS) is a large population-based cohort
92 study in southern India. The baseline study, APEDS I (1996-2000) assessed the prevalence of
93 eye diseases, the magnitude of vision impairment and its effect on quality of life, and barriers
94 to accessing eye health care services.¹³ The study had urban and rural sites. The next phase,
95 APEDS II (2009-2010) estimated migration and mortality rates by tracing participants
96 examined in APEDS I. It also identified participants willing to be re-examined.¹⁴ APEDS III
97 (2012-2016) re-examined rural participants about 15 (range 13-17) years after the baseline. We

98 could not identify the urban site because of development.¹⁴ In this publication, we report the
99 incidence of POAG and its risk factors.

100 **MATERIALS AND METHODS**

101 The study adhered to the tenets of the Declaration of Helsinki and was approved by the
102 Institutional Review Board of the Hyderabad Eye Research Foundation, L V Prasad Eye
103 Institute (LVPEI), Hyderabad, India and the London School of Hygiene & Tropical Medicine
104 (LSHTM), London. Written informed consent was obtained from all participants.

105 Methodology of APEDS has already been published in detail,^{13,14} and relevant
106 information is summarised here. At baseline, 10,293 participants were examined (7,771 in three
107 rural clusters and 2,522 in one urban cluster in the then undivided Andhra Pradesh state).¹⁴ The
108 second phase of feasibility (APEDS II), traced 5,447 (70.1%) of the original participants in the
109 three rural areas. In APEDS III, the rural areas were revisited after a mean of 15 years from
110 baseline to determine the incidence of eye diseases when 5395 participants (69.4% of the
111 original rural cohort) were re-examined using the same methodology.¹⁴ The study locations
112 were visited as follows: 2012/2013, Thoodukurthy village, Mahbubnagar district; 2013/2014,
113 Mudhole village, Adilabad district; and 2015/2016 Tanuku village, West Godavari district.

114 We collected socio-demographic, behavioral and past medical history data at baseline
115 (APEDS I) and follow-up (APEDS III).^{13,14} Comprehensive eye examinations were performed
116 at each site in eye health care facilities established by LVPEI as a part of its multi-tiered eye
117 health care network in India. The team was trained on the study protocol. There were four
118 clinical investigators in the study but only one was present at any given time. All clinical
119 investigators underwent inter-observer agreement assessment with the principal investigator
120 (PI, an experienced glaucoma specialist) for lens grading, gonioscopy and optic disc evaluation
121 before joining the study. The vertical cup-to-disc ratio (CDR) was assessed subjectively in
122 units of 0.05, with a kappa coefficient ranging between 0.69 and 0.81.¹⁵

123 Visual acuity (VA) testing was followed by streak retinoscopy and subjective refraction
124 by a trained optometrist or a vision technician when the presenting distance or near VA
125 exceeded 0.0 on Logarithm of minimum angle of resolution chart. We measured IOP using slit-
126 lamp mounted Goldmann applanation tonometer (Carl Zeiss Meditec, Inc). Tonometry was
127 repeated when the initial reading exceeded 21 mm Hg. Dark room gonioscopy was performed
128 with a short and narrow light beam (1-2 mm) to avoid pupil constriction. We used NMR-K 2-
129 mirror lens (Ocular Instruments, Bellevue, WA) analogous to baseline examination followed
130 by a Sussman 4 mirror lens (Volk, OH, USA) in APEDS III. The angle was defined as open
131 when the pigmented posterior trabecular meshwork was visible in $>180^\circ$ of the angle
132 circumference in the primary position without manipulation under dark room condition. Eyes
133 with an occludable angle underwent laser iridotomy prior to pupil dilation. We examined the
134 optic disc by slit-lamp biomicroscopy using a 78-D (Volk, OH, USA) lens. Indirect
135 ophthalmoscopy was performed to examine the entire fundus using a 20-D (Volk, OH, USA)
136 lens. Participants who were unable to visit the study site were examined at home using similar
137 methods.¹⁴

138 We performed automated perimetry using the threshold central 24-2 strategy (stimulus
139 size III) on a Humphrey Visual Field (HVF) analyzer (Humphrey Instruments Inc., San
140 Leandro, CA) on all participants with or suspected to have glaucoma.¹⁴ The additional criteria
141 to perform automated perimetry were IOP ≥ 22 mm Hg in one or both eyes and IOP difference
142 between the two eyes being ≥ 6 mm Hg. The test was repeated in case of unreliability. A visual
143 field was called glaucomatous when it correlated with optic disc damage and met ≥ 2 of
144 Anderson's criteria. Ocular biometry diagnostic procedures were added in APEDS III. Corneal
145 thickness, anterior chamber depth and lens thickness were measured using a portable
146 pachymeter (Tomey SP-100, Tomey Corporation, Noritakeshinmachi, Nagoya, Japan). Axial

147 length was measured using A Scan Ultrasound Biometry (Bio Medix Echo rule 2 serial no.
148 211887).¹⁴

149 **Definition of glaucoma**

150 The definition of glaucoma was based on the International Society of Geographical and
151 Epidemiological Ophthalmology (ISGEO) classification.¹⁶ We used normative data from the
152 Chennai Glaucoma Study (CGS) for the 97.5th and 99.5th percentile cutoffs for IOP and cup-
153 to-disc ratios.¹⁷ The rationale for using CGS data for cutoffs, and the three levels of evidence
154 to make the diagnosis of glaucoma in survey settings were explained earlier.¹⁸

155 The incidence of POAG was defined as the development of POAG during follow up
156 in at least one eye among participants who were phakic and who did not have glaucoma or
157 suspicion of glaucoma at baseline (APEDS I). Hyperopia and myopia were defined as spherical
158 equivalent ± 0.50 D or greater in a phakic eye. Systemic hypertension (HTN) was considered
159 present if a participant had a history of high blood pressure diagnosed by a physician and/or
160 was currently taking anti-hypertensive medication and/or had a blood pressure of $\geq 140/90$ mm
161 Hg. Diabetes mellitus (DM) was considered to be present if there was a positive history and/or
162 diabetic retinopathy was detected on clinical examination.

163 **Statistical analysis**

164 Shapiro-Wilk test was used to check normality of data distribution. Age at baseline (APEDS I)
165 was divided into 3 terciles (40-49, 50-59 and ≥ 60 years). Similarly, central corneal thickness
166 (CCT) was divided into 3 terciles (< 482 , 482-528 and > 528 microns). Mean IOP for the person
167 was calculated by averaging IOP measurements in right and left eyes. Intraocular pressure
168 difference was mean IOP measured in APEDS III minus that in APEDS I. The association of
169 POAG with baseline risk factors, such as age, IOP and systemic hypertension as well as
170 difference in right and left eye mean IOP between two follow up times and CCT was evaluated
171 first using univariate analysis, followed by multivariate analysis with logistic regression.

172 Variables which achieved statistical significance in the univariate analysis at the $P < 0.05$ level,
173 or were considered important on the basis of published literature or our clinical insight, were
174 included in the multivariate analysis. Model selection was performed using the Akaike
175 Information Criterion (AIC). The goodness of fit for logistic regression models was checked
176 using the Hosmer–Lemeshow test, and multi-collinearity was checked by calculating the
177 variance inflation factor (VIF). Statistical analyses were performed using Stata 12.1
178 (StataCorp, College Station, TX). A two-sided P value of < 0.05 was considered statistically
179 significant.

180 **RESULTS**

181 A total of 2,790 participants aged ≥ 40 years were examined in APEDS I. After a mean follow
182 up of 15 years, 1,470 (52.6%) were re-examined, 1241 (84.4%) of whom met the inclusion
183 criteria for the current study (**Figure 1**). Baseline demographic characteristics of participants,
184 non-participants and non-responders (participants who migrated, could not be traced or refused
185 to participate) have been published.¹⁵ Non-participants included non-responders and those who
186 had died since APEDS I.

187 Overall, 36 participants developed POAG over 15 years (**Table 1**). The 15-year
188 cumulative incidence of POAG (95% confidence interval) was 2.9% (2.03, 3.99) or about 0.2%
189 per year, assuming a linear incidence. Incident POAG was bilateral in 17 (47.2%) participants
190 and unilateral in 19 (52.8%). The diagnosis of POAG was based on ISGEO classification level
191 1 evidence (i.e., structural and functional evidence) in 21 (58.3%) participants and level 2
192 evidence (i.e., advanced structural damage with unproved visual field loss) in 15 (41.6%)
193 participants.

194 The IOP was > 21 mm Hg at the follow up visit (APEDS III) in five eyes of three
195 participants with unilateral incident POAG; the fellow eye in two participants had ocular
196 hypertension. Participants with or without incident POAG differed with respect to the

197 difference in mean of right and left eye IOPs between the two follow up times (**Table 2**). The
198 regression analysis did not reveal any additional risk factor (**Table 3**). The Hosmer-Lemeshow
199 test indicated a good fit of the regression model (P= 0.2).

200 **DISCUSSION**

201 Our population-based study of a rural cohort of a south Indian population reports a mean 15-
202 year incidence rate (95% CI) of POAG of 2.83 (2.6, 3.08) per 100 person years. Assuming a
203 linear incidence, the cumulative incidence of POAG in our study is about 0.2% per year. A less
204 marked reduction in mean IOP of both eyes between follow up times was a significant risk
205 factor.

206 Population-based studies show that the highest incidence of POAG is in populations of
207 African descent,^{6,7,12} which is consistent with prevalence studies (**Table 4**). Chronic diseases
208 like glaucoma can have a low incidence in aging populations despite a high prevalence, e.g.,
209 POAG incidence study from Australia and the Netherlands.⁸ However, comparison of age-
210 standardized data is needed to confirm this observation.

211 Apart from ancestry, the geographical variation in incidence of POAG could be
212 attributed to methodological differences across studies; the most important being whether
213 participants who were POAG suspects at baseline were included or not. For example, in the
214 Melbourne Visual Impairment Project, the incidence of POAG was five times higher [2.7%
215 (95% CI: 1.8, 3.7)] compared with 0.54% per year, if suspects were included in the analysis.⁸
216 Other methodological differences include how POAG was defined, including the use of
217 relevant normative data, the methods used for clinical examination; such as IOP measurement
218 and visual field analysis, and the steps to achieving consensus on the diagnosis of POAG.

219 The cumulative incidence of POAG in our study is similar to that reported in the Indian
220 population in Singapore⁵ but is lower than in the rural cohort of Chennai Eye Disease Incidence
221 Study (CEDIS).⁴ The latter studied the same ethnic group as APEDS. However, the age-

222 specific incidence rate in our study among those aged 40-49 and 50-59 years is higher than in
223 the same age-groups but was lower amongst those aged 60 years and above in the other two
224 studies.^{4,5} The latter likely reflects a shorter life expectancy among rural residents in India
225 compared with Indians living in Singapore. The relatively low number of participants aged 60
226 years and above in our study may explain why age was not a significant risk factor, unlike all
227 other studies.^{4-12,19}

228 We observed a significant reduction in the mean IOP of right and left eyes between
229 APEDS I and APEDS III, despite adjusting for CCT. Similar findings have been reported in
230 other studies of Asian populations²⁰⁻²⁵ but not in Caucasians or populations of African
231 descent.²⁶⁻²⁸ In our study, the longitudinal difference in mean IOP of right and left eye was less
232 pronounced amongst participants who developed POAG than those who did not ($P < 0.1$)
233 indicating that longitudinal change in IOP is a risk factor for POAG. The relationship between
234 age and IOP may be explained by a reduction in aqueous humour production and/or a decrease
235 in the resistance to aqueous outflow, but this requires further investigation. Thirty-three
236 (91.6%) participants with incident POAG in our study had an IOP of ≤ 21 mm Hg, which is
237 comparable to CEDIS (77%)⁴ and the Indian population in Singapore (85%),⁵ but is unlike the
238 black population (41.6%).⁷ An important caveat is that IOP was only measured once and not
239 throughout the day to identify diurnal variation.

240 Central corneal thickness can vary across populations. An inverse relationship between
241 odds of incident POAG and CCT was seen in our study. Nevertheless, low statistical power did
242 not allow us to sufficiently explore the role of CCT as a risk factor. Central corneal thickness
243 wasn't a significant risk factor in other studies of Asian populations,^{4,5} unlike in Black
244 populations.^{12,29} However, whether the relationship between CCT and POAG is due to
245 underestimation of IOP in thin corneas or CCT is an independent risk factor, reflecting altered

246 biomechanical and structural characteristics of ocular tissues, has not been conclusively
247 determined.

248 Our study has a few limitations. We did not have information on family history of
249 POAG. It is attributable to a limited access to healthcare in rural India. Intraocular pressure is
250 known to vary during the 24-hour cycle and between visits. Multiple IOP readings over the day
251 of examination can provide a better IOP profile.³⁰ Even so, it would have been resource
252 intensive for a population-based study. This factor is unlikely to have had a significant impact
253 on the incidence rate as the diagnosis of POAG was largely based on evidence of structural
254 damage to the optic disc. We did not perform ocular biometry at baseline but added it in
255 APEDS III. Yet, considering the low rate of change in CCT over time,³¹ not having CCT data
256 at baseline is unlikely to affect the outcome of our study. The number of participants with
257 diabetes was low in our study as we relied on self-reporting of diabetes and performed blood
258 sugar testing only on selected participants.¹⁴ This limited our ability to explore diabetes as a
259 risk factor for POAG. The risk factors were fixed at baseline, but in real life, these factors can
260 vary over time. The size of the at-risk population was least in our study compared to the other
261 incidence studies on POAG,⁴⁻¹¹ with an exception.¹² However, ours is the longest-ever study
262 on the incidence of POAG, and the fundamental reason for non-participation was mortality
263 (figure 1). We have published the incidence of mortality in APEDS.³² We compared mean IOP
264 of right and left eye instead of IOP in the worse or affected eye or a randomly selected eye.
265 This is because the fellow eye in participants with unilateral incident POAG may not be normal
266 since adaptive optics has shown damaged RNFL at subclinical stage of glaucoma.³³

267 **Conclusion**

268 This long-term population-based study reports the incidence rate of POAG in the rural
269 population of southern India. The results indicate longitudinal change in IOP, possibly due to
270 altered aqueous humour dynamics with advancing age as a novel risk factor. The rate of

271 incident glaucoma was relatively low, such that the power to analyze risk factors with more
272 modest effect sizes is decreased. Nevertheless, studies on the incidence of POAG are limited
273 and ours might be a valuable addition to the literature. We recommend that a standardized
274 methodology be used for future studies to enable comparisons.

275

276 Supplementary information is available at Eye Journal's website.

277 **Author Contribution Statement:**

278 NSC was responsible for data analysis, drafted the manuscript, approved the final version and
279 agreed to be accountable for all aspects of the work in ensuring that questions related to the
280 accuracy or integrity of any part of the work are appropriately investigated and resolved. RCK
281 conceived and designed the work that led to the submission, acquired data, and played an
282 important role in interpreting the results, revised the manuscript, approved the final version and
283 agreed to be accountable for all aspects of the work in ensuring that questions related to the
284 accuracy or integrity of any part of the work are appropriately investigated and resolved. CG
285 played an important role in interpreting the results, revised the manuscript, approved the final
286 version and agreed to be accountable for all aspects of the work in ensuring that questions
287 related to the accuracy or integrity of any part of the work are appropriately investigated and
288 resolved. All the remaining authors acquired data, played a role in interpreting the results,
289 revised the manuscript, approved the final version and agreed to be accountable for all aspects
290 of the work in ensuring that questions related to the accuracy or integrity of any part of the
291 work are appropriately investigated and resolved.

292 **Data availability statement:**

293 The datasets generated during and/or analysed during the current study are available from the
294 corresponding author on reasonable request.

295

296 **References**

- 297 1. Jonas JB, Aung T, Bourne RR, Bron AM, Ritch R, Panda-Jonas S. Glaucoma. *Lancet*
298 **390(10108)**, 2183-2193 (2017)
- 299 2. Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of
300 glaucoma and projections of glaucoma burden through 2040: a systematic review and
301 meta-analysis. *Ophthalmology* **121**, 2081-90 (2014)
- 302 3. Tham YC, Cheng CY. Associations between chronic systemic diseases and primary
303 open angle glaucoma: an epidemiological perspective. *Clin Exp Ophthalmol* **45**, 24-32
304 (2017)
- 305 4. Vijaya L, Rashima A, Panday M, Choudhari NS, Ramesh SV, Lokapavani V, et al.
306 Predictors for incidence of primary open-angle glaucoma in a South Indian population:
307 the Chennai eye disease incidence study. *Ophthalmology* **121**, 1370-6 (2014)
- 308 5. Koh V, Tham YC, Tan NYQ, Yu M, Thakur S, Teo ZL, et al. Six-Year Incidence and
309 Risk Factors of Primary Glaucoma in the Singapore Indian Eye Study. *Ophthalmol*
310 *Glaucoma* **4**, 201-208 (2021)
- 311 6. Leske MC, Connell AM, Wu SY, Nemesure B, Li X, Schachat A, et al. Incidence of
312 open-angle glaucoma: the Barbados Eye Studies. The Barbados Eye Studies Group.
313 *Arch Ophthalmol* **119**, 89-95 (2001)
- 314 7. Leske MC, Wu SY, Honkanen R, Nemesure B, Schachat A, Hyman L, et al; Barbados
315 Eye Studies Group. Nine-year incidence of open-angle glaucoma in the Barbados Eye
316 Studies. *Ophthalmology* **114**, 1058-64 (2007)
- 317 8. Mukesh BN, McCarty CA, Rait JL, Taylor HR. Five-year incidence of open-angle
318 glaucoma: the visual impairment project. *Ophthalmology* **109**, 1047-51 (2002)

- 319 9. de Voogd S, Ikram MK, Wolfs RC, Jansonius NM, Hofman A, de Jong PT. Incidence
320 of open-angle glaucoma in a general elderly population: the Rotterdam Study.
321 *Ophthalmology* **112**, 1487-93 (2005)
- 322 10. Springelkamp H, Wolfs RC, Ramdas WD, Hofman A, Vingerling JR, Klaver CC, et al.
323 Incidence of glaucomatous visual field loss after two decades of follow-up: the
324 Rotterdam Study. *Eur J Epidemiol* **32**, 691-699 (2017)
- 325 11. Varma R, Wang D, Wu C, Francis BA, Nguyen BB, Chopra V, et al; Los Angeles
326 Latino Eye Study Group. Four-year incidence of open-angle glaucoma and ocular
327 hypertension: the Los Angeles Latino Eye Study. *Am J Ophthalmol* **154**, 315-325.e1
328 (2012)
- 329 12. Mwanza JC, Tulenko SE, Barton K, Herndon LW, Mathenge E, Hall A, et al. Eight-
330 Year Incidence of Open-Angle Glaucoma in the Tema Eye Survey. *Ophthalmology*
331 **126**, 372-380 (2019)
- 332 13. Dandona R, Dandona L, Naduvilath TJ, Nanda A, McCarty CA. Design of a
333 population-based study of visual impairment in India: The Andhra Pradesh Eye Disease
334 Study. *Indian J Ophthalmol* **45**, 251-7 (1997)
- 335 14. Khanna RC, Murthy GV, Marmamula S, Mettla AL, Giridhar P, Banerjee S, et al.
336 Longitudinal Andhra Pradesh Eye Disease Study: rationale, study design and research
337 methodology. *Clin Exp Ophthalmol* **44**, 95-105 (2016)
- 338 15. Choudhari NS, Khanna RC, Marmamula S, Mettla AL, Giridhar P, Banerjee S, et al.
339 Fifteen-Year Incidence Rate of Primary Angle Closure Disease in the Andhra Pradesh
340 Eye Disease Study. *Am J Ophthalmol* **229**, 34-44 (2021)
- 341 16. Foster PJ, Buhrmann R, Quigley HA, Johnson GJ. The definition and classification of
342 glaucoma in prevalence surveys. *Br J Ophthalmol* **86**, 238-42 (2002)

- 343 17. Vijaya L, George R, Arvind H, Baskaran M, Ve Ramesh S, Raju P, et al. Prevalence of
344 primary angle-closure disease in an urban south Indian population and comparison with
345 a rural population. The Chennai Glaucoma Study. *Ophthalmology* **115**, 655-660.e1
346 (2008)
- 347 18. Senthil S, Garudadri C, Khanna RC, Sannapaneni K. Angle closure in the Andhra
348 Pradesh Eye Disease Study. *Ophthalmology* **117**, 1729-35 (2010)
- 349 19. Khanna RC, Marmamula S, Pendri P, Mettla AL, Giridhar P, Banerjee S, et al.
350 Incidence, Incident Causes, and Risk Factors of Visual Impairment and Blindness in a
351 Rural Population in India: 15-Year Follow-up of the Andhra Pradesh Eye Disease
352 Study. *Am J Ophthalmol* **223**, 322-332 (2021)
- 353 20. Chua J, Chee ML, Chin C, Tham YC, Tan N, Lim SH, et al. Inter-relationship between
354 ageing, body mass index, diabetes, systemic blood pressure and intraocular pressure in
355 Asians: 6-year longitudinal study. *Br. J. Ophthalmol* **103**, 196–202 (2019)
- 356 21. Lee MK, Cho SI, Kim H, Song YM, Lee K, Kim JI, et al. Epidemiologic Characteristics
357 of Intraocular Pressure in the Korean and Mongolian Populations: The Healthy Twin
358 and the GENDISCAN Study. *Ophthalmology* **119**, 450–457 (2012)
- 359 22. Zhou Q, Liang Y, Wong TY, Yang XH, Lian L, Zhu D, et al. Intraocular Pressure and
360 its Relationship to Ocular and Systemic Factors in a Healthy Chinese Rural Population:
361 The Handan Eye Study. *Ophthalmic Epidemiol* **19**, 278–284 (2012)
- 362 23. Kawase K, Tomidokoro A, Araie M, Iwase A, Yamamoto T, Tajimi Study Group;
363 Japan Glaucoma Society. Ocular and systemic factors related to intraocular pressure in
364 Japanese adults: The Tajimi study. *Br J Ophthalmol* **92**, 1175–1179 (2008)
- 365 24. Baek SU, Kee C, Suh W. Longitudinal analysis of age-related changes in intraocular
366 pressure in South Korea. *Eye* **29**, 625–629 (2015)

- 367 25. Nomura H, Ando F, Niino N, Shimokata H, Miyake Y. The relationship between age
368 and intraocular pressure in a Japanese population: The influence of central corneal
369 thickness. *Curr Eye Res* **24**, 81–85 (2002)
- 370 26. Klein BE, Klein R, Linton KL. Intraocular pressure in an American community. The
371 Beaver Dam Eye Study. *Investig Ophthalmol Vis Sci* **33**, 2224–2228 (1992)
- 372 27. Wu SY, Leske MC. Associations with Intraocular Pressure in the Barbados Eye Study.
373 *Arch Ophthalmol* **115**, 1572–1576 (1997)
- 374 28. Gabelt BT, Kaufman PL. Changes in aqueous humour dynamics with age and
375 glaucoma. *Prog Retin Eye Res* **24**, 612-37 (2005)
- 376 29. Leske MC, Wu SY, Hennis A, Honkanen R, Nemesure B; BESs Study Group. Risk
377 factors for incident open-angle glaucoma: the Barbados Eye Studies. *Ophthalmology*
378 **115**, 85-93 (2008)
- 379 30. Konstas AG, Kahook MY, Araie M, Katsanos A, Quaranta L, Rossetti L, et al. Diurnal
380 and 24-h Intraocular Pressures in Glaucoma: Monitoring Strategies and Impact on
381 Prognosis and Treatment. *Adv Ther.* **35**, 1775-1804 (2018)
- 382 31. Mwanza JC, Tulenko SE, Budenz DL, Mathenge E, Herndon LH, Kim HY, et al.
383 Longitudinal Change in Central Corneal Thickness in the Tema Eye Survey. *Am J*
384 *Ophthalmol* **186**, 10-18 (2018)
- 385 32. Khanna RC, Murthy GV, Giridhar P, Krishnaiah S, Pant HB, Palamaner Subash
386 Shantha G, et al. Cataract, visual impairment and long-term mortality in a rural cohort
387 in India: the Andhra Pradesh Eye Disease Study. *PLoS One* **25**, e78002 (2013)
- 388 33. Choudhari NS, Kumar S, Richhariya A, Krishnamurthy R, Priya R, Garudadri CS.
389 Adaptive optics scanning laser ophthalmoscopy may support early diagnosis of
390 glaucoma. *Indian J Ophthalmol* **70**, 2877-2882 (2022)

Rural cohort in APEDS I
aged ≥ 40 years:
n= 2790

Non-participants in APEDS III:
n= 1320

Died, n= 1106 (83.7%)
Migrated, n= 92 (6.9%)
Not traceable, n= 51 (3.8%)
Refused, n= 71 (5.3%)

Participants available for APEDS III:
n= 1470 (52.6% of original cohort)

Participants with following diagnosis in APEDS I:
Primary angle closure disease, n= 32
Primary open angle glaucoma, n= 13
Glaucoma suspect, n= 1

Excluded:
n= 229

Participants undergoing cataract surgery
since APEDS I, n= 180

Data not available for both eyes, n= 3

Participants examined in APEDS III:
n= 1241 (44.4% of original cohort)

Table 1: Incidence of POAG by age at baseline in males and females

Age group (years)	Male		Female		Total		Incidence rate/100 person years (95% CI*)
	At risk	n (%) (95% CI*)	At risk	n (%) (95% CI*)	At risk	n (%) (95% CI*)	
40 - 49	325	8 (2.46) (1.06, 4.79)	379	11 (2.9, 1.45, 5.13)	704	19 (2.69) (1.63, 4.18)	2.73 (2.42, 3.06)
50 - 59	175	8 (4.57) (1.99, 8.8)	187	5 (2.67) (0.87, 6.12)	362	13 (3.59) (1.92, 6.06)	3.4 (2.93, 3.93)
≥ 60	80	2 (2.5) (0.3, 8.74)	95	2 (2.1) (0.25, 7.39)	175	4 (2.28) (0.62, 5.74)	2.1 (1.58, 2.73)
Total	580	18 (3.1) (1.84, 4.86)	661	18 (2.72) (1.62, 4.26)	1241	36 (2.9) (2.03, 3.99)	2.83 (2.6, 3.08)

*CI: Confidence Interval

Table 2: Comparison of participants with or without incident POAG

Variable	Participants 1241 n (% or Range)	Without POAG 1205 (97.1%) n (% or Range)	With POAG 36 (2.9%) n (% or Range)	P value
Study center, n (%)				
Mahbubnagar	488 (39.3)	471 (96.5)	17 (3.4)	0.5
Adilabad	379 (30.5)	368 (97.1)	11 (2.9)	
West Godavari	374 (30.1)	366 (97.8)	8 (2.1)	
Age Group (years), n (%)				
40- 49	704 (56.7)	685 (97.3)	19 (2.7)	0.62
50- 59	362 (29.1)	349 (96.4)	13 (3.5)	
≥60	175 (14.1)	171 (97.7)	4 (2.2)	
Male sex, n (%)	580 (46.7)	562 (96.9)	18 (3.1)	0.69
Myopia > ±0.50 D spherical equivalent, n (%)	305 (24.5)	296 (97)	9 (2.9)	0.95
Hyperopia > ±0.50 D spherical equivalent, n (%)	206 (16.6)	197 (95.6)	9 (4.3)	0.16
Baseline Mean IOP in mm Hg Median (Range)	Missing 16 ¹ 15.5 (8, 20)	15.5 (8, 20)	15.5 (11, 19.5)	0.85 (MW)
Difference in mean IOP between APEDS III and APEDS I (mmHg) Median (Range)	Missing 74 ¹ -2.5 (-14.5, 14.5)	-2.5 (-14.5, 14.5)	-0.75 (-7.5, 9)	<0.01 (MW)
Central corneal thickness, APEDS III, right eye (µm), n (%)				
>528	Missing 62 ¹ 291 (24.6)	283 (97.2)	8 (2.7)	0.44
482 - 528	600 (50.8)	584 (97.3)	16 (2.6)	
<482	288 (24.4)	276 (95.8)	12 (4.1)	
Axial length, APEDS III, right eye (mm) Median (Range)	Missing 188 ¹ 22.5 (18.5, 28.6)	22.5 (18.5, 28.6)	22.7 (20.18, 24.92)	0.31
Body mass index (kg/m ²), n (%)				
18.5 – 24.99	Missing 27 ² 599 (49.3)	583 (97.3)	16 (2.6)	0.61
<18.5	502 (41.3)	485 (96.6)	17 (3.3)	
25 – 29.9	91 (7.5)	90 (98.9)	1 (1.1)	
≥30	22 (1.8)	21 (95.4)	1 (4.5)	
Systemic hypertension, n (%)	Missing 21 ² 451 (36.9)	442 (98)	9 (2)	0.16
Diabetes mellitus, n (%)	12 (0.9)	12 (100)	0	0.54
Smoking status, n (%)				
Never	777 (62.6)	758 (97.5)	19 (2.4)	0.36
Past	80 (6.4)	78 (97.5)	2 (2.5)	
Current	384 (30.9)	369 (96)	15 (3.9)	

Alcohol consumption, n (%)				
Never	711 (57.2)	689 (96.9)	22 (3)	
Past	74 (5.9)	73 (98.6)	1 (1.3)	
Current	456 (36.7)	443 (97.1)	13 (2.8)	0.69
Education level (years), n (%)				
No education	801 (64.5)	774 (96.6)	27 (3.3)	
Education (school or higher)	440 (35.4)	431 (97.9)	9 (2)	0.18

POAG: Primary open angle glaucoma, M. Nagar: Mahabubnagar, IOP: Intra-ocular pressure; MW:

Mann Whitney

All the risk factors were assessed at the baseline unless stated otherwise.

1: Not missing from any participant with incident POAG

2: Missing in one participant with incident POAG

Table 3: Logistic regression to assess the association between incident Primary Open Angle Glaucoma and risk factors

Variable	Sub-Variable	Univariate Regression		Multivariate Regression	
		Odds Ratio (95% CI)	P value	Odds Ratio (95% CI)	P value
Study Center	Mahbubnagar				
	Adilabad	0.82 (0.38, 1.78)	0.63		
	West Godavari	0.6 (0.25, 1.41)	0.24		
Age group	40 - 49	1.0			
	50 - 59	1.34 (0.65, 2.75)	0.42	1.29 (0.6, 2.78)	0.51
	60 and above	0.84 (0.28, 2.51)	0.76	0.82 (0.22, 2.99)	0.77
Male sex		1.14 (0.58, 2.22)	0.69	1.23 (0.6, 2.52)	0.55
Myopia, n (%)		1.02 (0.47, 2.2)	0.95	0.83 (0.34, 1.99)	0.68
Hyperopia, n (%)		1.7 (0.78, 3.68)	0.17		
Mean IOP (APEDS I)		0.96 (0.81, 1.14)	0.72		
IOP difference (Difference in mean IOP, APEDS III minus APEDS I)		1.17 (1.07, 1.28)	<0.01	1.15 (1.05, 1.27)	<0.01
Central corneal thickness (Microns) of Right Eye (APEDS III)	>528	1.0			
	482 - 528	0.96 (0.4, 2.29)	0.94	1.45 (0.54, 3.86)	0.45
	<482	1.53 (0.61, 3.82)	0.35	2.57 (0.91, 7.25)	0.07
Axial Length of Right eye (APEDS III)		1.19 (0.83, 1.72)	0.33		
BMI	18.5 – 24.99	1.0			
	<18.5	1.2 (0.59, 2.42)	0.6	1.12 (0.53, 2.34)	0.75
	25 – 29.9	0.39 (0.05, 3)	0.36	0.42 (0.05, 3.32)	0.41
	≥30	1.8 (0.22, 14.3)	0.57	2.32 (0.26, 20.11)	0.44
Systemic Hypertension		0.58 (0.27, 1.25)	0.16	0.62 (0.27, 1.41)	0.25
Diabetes Mellitus		1.0			
Smoking Status	Never smoker	1.0			
	Past smoker	1.02 (0.23, 4.47)	0.97		

	Current smoker	1.62 (0.81, 3.22)	0.16		
Alcohol consumption	Never alcohol	1.0			
	Past alcohol	0.42 (0.05, 3.22)	0.41		
	Current alcohol	0.91 (0.45, 1.84)	0.81		
Education level (years)	No Education	1.0			
	Education (School or Higher)	0.59 (0.27, 1.28)	0.18		

All the risk factors were assessed at the baseline unless stated otherwise.

CI: Confidence interval, APEDS: Andhra Pradesh Eye Disease Study, IOP: Intra-ocular pressure, BMI: Body mass index

Table 4. Comparison with previous population-based studies on incidence of primary open angle glaucoma (POAG)

Study/population/ year	Ethnic group	No. at risk	Age (years), Minimum (mean \pm SD)	Follow up (years)	Incident cases, n	Incidence rate / 1000 person years)	Cumulative incidence % (95% CI)	Annual cumulative incidence %	Risk Factors
Melbourne Visual Impairment Project, ⁸ 2002	Mainly white	2427	40 (58.7 \pm 11.4)	5	12		0.5 (0.3-0.7)	0.1	Age, higher IOP, H/O α blocker, presence of PXF, CDR >0.7
Rotterdam Eye Study, ¹⁰ 2017	Multi- ethnic	3939	55	12	48	1.0 (0.7-1.3)	1.2 (0.9-1.5)	0.1	Age, baseline IOP, IOP lowering Rx, family history, body mass index
Rotterdam Eye Study, ⁹ 2005	Multi- ethnic	3842	55, 65.7 \pm 6.9	5	29	1.2 (0.8-1.7)	0.6	0.12	Age, ocular HTN at baseline, fellow eye of unilateral POAG at baseline
Singapore Indian Eye Study, ⁵ 2021	Indian	2158	40 (56.5 \pm 9.2)	6	37		1.37 ^{&} (0.94-1.96)	0.22	Older age, higher IOP, raised CDR
*CEDIS, ⁴ 2014	South Indian, rural	2469	40	6	59		1.9 (1.4-2.4)	0.31	
Barbados Eye Study, ⁷ 2007	Black	3222	40 (56.9 \pm 11.3)	9	125		4.4 (3.7-5.2)	0.48	Older age, family history, low ocular MPP, thinner CCT, higher IOP at baseline (HTN protective)
*CEDIS, ⁴ 2014	South Indian	4316	40 (58.4 \pm 9.7)	6	129		2.9 (2.4-3.4)	0.48	Older age, urban, higher IOP, myopia, higher AXL (HTN protective)
Barbados Eye Study, ⁶ 2001	Black	2989	40 (57.5 \pm 11.5)	4	67		2.2 (1.7-2.8)	0.55	Older age, men, higher IOP, (OHT) or suspect at baseline
Los Angeles Latino Eye Study, ¹¹ 2012	Latin American	3772	40 (54.6 \pm 10.3)	4	87		2.3 (1.8-2.8)	0.57	Older age, fellow eye of POAG

Tema Eye Survey, ¹² 2018	West African, urban	1101	40	8	51		4.7 (4.5-4.8)	0.59 (0.5-0.6)	Male gender, older age, higher IOP, larger CDR, thinner central cornea
**APEDS. Current study	South Indian, rural	1241	40 (49.4±7.8)	15	36	0.2 (0.2-0.3)	2.9 (2.0-3.9)	0.19	IOP difference at two time points

&: Age-standardized incidence; *CEDIS: Chennai Eye Disease Incidence Study; **APEDS: Andhra Pradesh Eye Disease Study

AXL: Axial length; BMI: Body mass index; CCT: Central corneal thickness; CDR: Vertical cup-to-disc ratio; CI: Confidence interval; HTN: Systemic hypertension; IOP: Intra-ocular pressure; MPP: Mean perfusion pressure; OAG: Open angle glaucoma; OHT: Ocular hypertension; PXF: Pseudo-exfoliation; SD: Standard Deviation